Literature DB >> 6506139

High-performance liquid chromatographic measurement of cyclophosphamide in serum.

R W Hardy, C Erlichman, S J Soldin.   

Abstract

The analysis of cyclophosphamide [N,N-bis(2-chlorethyl)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine -2-oxide] by high-performance liquid chromatography using ultraviolet detection is described. The method will enable measurement of serum concentrations of cyclophosphamide over a period of approximately 24 h after a dose of 150 mg, and requires 1 ml of serum. The between-day precision of the assay at concentrations of 0.3, 1.0, and 15.0 mg/L generated coefficients of variation of 11.8, 12.2, and 7.7%, respectively. Percentages of analytical recovery of cyclophosphamide and internal standard (5-ethyl-5-p-tolylbarbituric acid) were 63 and 73%, respectively. Preliminary data providing the half-life for two patients with normal renal function are presented.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506139     DOI: 10.1097/00007691-198409000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Authors:  Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

5.  Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer.

Authors:  M J Moore; C Erlichman; J J Thiessen; P S Bunting; R Hardy; I Kerr; S Soldin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.